Injection delivery system developer ApiJect announced that it promoted Molly Weaver to the position of chief operating officer. Weaver’s background includes both the pharmaceutical and medical technology markets. Her experience spans strategy, product development and execution across a broad range of industrialization and drug delivery systems. Most recently, Weaver served as chief technology officer at ApiJect. […]
Pharmaceuticals
Stevanato Group expands large-volume drug delivery offerings
Stevanato Group announced today that it expanded the capacity of its Vertiva on-body device for subcutaneous large-volume drug delivery. The Italy-based company says its Vertiva platform now covers 10mL volumes. It plans to present the latest Vertiva development at CPhI Milan next month. Vertiva features a single-use injection unit (or pod) and a multi-use smart […]
PCI Pharma Services makes $365M investment in drug delivery device manufacturing
PCI Pharma Services announced that it’s investing more than $365 million in infrastructure to support assembly and packaging efforts. The investment supports the clinical- and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats. PCI Pharma plans to put its investment toward new and […]
Fresenius Kabi recalls and removes some Ivenix infusion pump administration sets from market
The FDA issued a notice outlining a serious recall of Ivenix infusion pump administration sets from Fresenius Kabi. This recall involves removing certain devices from where they are used or sold. The FDA identified it as the most serious type as it may cause serious injury or death. Fresenius Kabi recalled certain lots of the […]
Tandem wins clearance for t:slim X2 pump with Eli Lilly fast-acting insulin in Europe
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its t:slim X2 pump. The company can now offer its automated insulin delivery (AID) system with Eli Lilly’s Lyumjev (insulin lispro-aabc injection) ultra-rapid-acting insulin in Europe. Previously, the t:slim X2 pump had clearance for use with Humalog and […]
BD launches new prefillable syringe, expands platform capacity
BD (NYSE:BDX) announced today that it launched its Neopak XtraFlow glass prefillable syringe and expanded the capacity for the platform. The company said the launch and expansion aim to serve the growing market for biologic therapies. Neopak glass prefillable syringes address key development needs for biologic drugs, BD said in a news release. The syringes […]
Aptar Pharma inks dev deal with Pulmotree for non-propellant liquid inhaler platform
Aptar Pharma announced that it entered into an exclusive collaboration agreement with Pulmotree to develop a liquid inhaler platform. The collaboration enables Aptar to lead the development and promotion of the Kolibri non-propellant liquid inhaler (NPLI) platform. Under the agreement, Aptar intends to provide Pulmotree with full support to accelerate growth. The company serves as […]
Vaxxas begins avian flu vaccine trial using high-density microarray delivery patch
Vaxxas announced that it began a multi-center Phase I clinical trial of a vaccine against avian flu using its high-density microarray patch. The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed its HD-MAP technology to use an ultra-high-density array of micro projections, invisible to the human eye. Applied to […]
NanoSyrinx raises $13M to support nanosyringe tech
NanoSyrinx, a synthetic biology company developing nanosyringes, announced that it closed a £10 million ($13 million) financing round. BGF, Octopus Ventures and M Ventures led the financing. Existing investors IQ Capital and Meltwind also participated. According to a news release, pharmaceutical giant Eli Lilly took part in the funding round as well. NanoSyrinx also named […]
Eli Lilly has positive once-weekly insulin data
Eli Lilly (NYSE:LLY) today announced positive results from phase 3 clinical trials evaluating its once-weekly insulin efsitora alfa. The Indianapolis-based pharmaceutical giant evaluated its once-weekly insulin in insulin-naïve adults in the QWINT-1 study. These adults have type 2 diabetes and are using basal insulin for the first time. Additionally, Eli Lilly’s QWINT-3 trial looked at […]
